Who are dex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexmedetomidine-esketamine combination, Dexmetomidine intravenously, Precedex (Dexmedetomidine), dexmedetomidine 2, Simbrinza 0.2%-1% Ophthalmic Suspension, ropivacaine mixed with dexmedetomidine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

dex — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dex (dex) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Anesthesiology.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

dex (dex) — The Cleveland Clinic. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that induces sedation and reduces sympathetic nervous system activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
dex TARGET	dex	The Cleveland Clinic	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Dexmedetomidine-esketamine combination	Dexmedetomidine-esketamine combination	Peking University First Hospital	marketed	Sedative-analgesic combination	Alpha-2 adrenergic receptor; NMDA receptor
Dexmetomidine intravenously	Dexmetomidine intravenously	KAT General Hospital	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Precedex (Dexmedetomidine)	Precedex (Dexmedetomidine)	Icahn School of Medicine at Mount Sinai	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
dexmedetomidine 2	dexmedetomidine 2	National Cancer Institute, Egypt	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Simbrinza 0.2%-1% Ophthalmic Suspension	Simbrinza 0.2%-1% Ophthalmic Suspension	Prairie Eye Center	marketed	Fixed-dose combination of carbonic anhydrase inhibitor and alpha-2 adrenergic agonist	Carbonic anhydrase II; alpha-2 adrenergic receptor
ropivacaine mixed with dexmedetomidine	ropivacaine mixed with dexmedetomidine	The First Hospital of Qinhuangdao	marketed	Local anesthetic combination with alpha-2 adrenergic agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

Allergan · 3 drugs in this class
Eye & ENT Hospital of Fudan University · 2 drugs in this class
National Cancer Institute, Egypt · 2 drugs in this class
The University of Hong Kong · 2 drugs in this class
Sindh Institute of Urology and Transplantation · 2 drugs in this class
Fayoum University Hospital · 1 drug in this class
First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dex — Competitive Intelligence Brief. https://druglandscape.com/ci/dex. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing